Results 271 to 280 of about 148,910 (315)
Some of the next articles are maybe not open access.
Diabetes Research and Clinical Practice, 2018
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Ritwika, Mallik, Tahseen A, Chowdhury
openaire +2 more sources
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability.
Ritwika, Mallik, Tahseen A, Chowdhury
openaire +2 more sources
Regulatory Toxicology and Pharmacology, 2018
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +2 more sources
This review investigates the different biological effect of Metformin (MET) in different conditions. MET is an oral antidiabetic drug used for the treatment of type 2 diabetes mellitus (T2DM) particularly in overweight people. The main mechanism of action of the MET is inhibition of hepatic glucose production and reduction of insulin resistance.
Tuğba Adak +3 more
openaire +2 more sources
Annals of Internal Medicine, 2002
Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent.
Dmitri, Kirpichnikov +2 more
openaire +2 more sources
Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent.
Dmitri, Kirpichnikov +2 more
openaire +2 more sources
Diabetes & Metabolism, 2014
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
J D, Lalau +4 more
openaire +2 more sources
These case reports demonstrate that, at the individual level, blood metformin concentrations and metformin effects on lactate do not always correlate.We report here on two unusual cases: metformin accumulation in the absence of hyperlactataemia; and metformin-induced hyperlactataemia with no metformin accumulation.Patient #1 presented with severe ...
J D, Lalau +4 more
openaire +2 more sources
Renoprotective Effects of Metformin
Nephron, 2017<b><i>Background/Aims:</i></b> It has become clear that metformin exerts pleiotropic actions beyond its glucose-lowering agent effect. In this review, we summarise the state of the art concerning the potential renoprotective effects of metformin in vitro, animal models and clinical nephrology. <b><i>Methods:</i>
de Broe, Marc E. +2 more
openaire +4 more sources
Clinical Pharmacokinetics of Metformin
Clinical Pharmacokinetics, 2011Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusion through cell membranes should be
Graham, Garry G. +12 more
openaire +5 more sources
Drugs, 2005
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources
The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output. Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control.
openaire +2 more sources
Scandinavian Journal of Haematology, 1969
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire +2 more sources
A clinical series of 40 patients was observed for 5 months, in the course of which every patient took 1.5 g. metformin daily for 3 months. No increase in fibrinolytic activity was demonstrable by euglobulin lysis test during the course of treatment. Nor did the fibrinogen and cholesterol values change. Blood glucose decreased.
openaire +2 more sources